FindTrial
Sign In

Thoracic Radiation Therapy (TRT)

RADIATION5 trials

Sponsors

Eli Lilly and Company, Merck Sharp & Dohme LLC, Hoffmann-La Roche, Genfleet Therapeutics (Shanghai) Inc., Sichuan University

Conditions

Carcinoma, Small Cell LungExtensive-stage Small-cell Lung CancerNSCLC, Stage IIINon Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 2

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)
CompletedNCT03631784
Merck Sharp & Dohme LLCNon-small Cell Lung Cancer
Start: 2018-10-19End: 2024-03-19Updated: 2025-03-25
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
CompletedNCT04622228
Hoffmann-La RocheCarcinoma, Small Cell Lung
Start: 2020-12-16End: 2024-06-30Updated: 2024-07-29
A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC
CompletedNCT05386888
Genfleet Therapeutics (Shanghai) Inc.NSCLC, Stage III
Start: 2022-09-09End: 2023-12-31Updated: 2025-10-02
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
RecruitingNCT05765825
Sichuan UniversityExtensive-stage Small-cell Lung Cancer
Start: 2023-03-07End: 2025-12-31Target: 61Updated: 2024-06-20

Phase 3

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
CompletedNCT00686959
Eli Lilly and CompanyNon Small Cell Lung Cancer
Start: 2008-09-30End: 2014-11-30Updated: 2016-06-28

Related Papers

Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer.
2024-07-0331 citations
Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.
Journal of Clinical Oncology2024-06-015 citations
Abstract CT219: Efficacy and safety of Low dose radiotherapy (LDRT) concurrent Atezolizumab (Atezo) plus chemotherapy as first line (1L) therapy for ES-SCLC: Primary analysis of Phase II MATCH study
Cancer Research2023-04-142 citations
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
Journal of Clinical Oncology2022-06-0127 citations
Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.
Journal of Clinical Oncology2022-06-016 citations
Striking effect of low-dose radiotherapy combined with PD-1 blockade on small cell lung cancer in mice and refractory patients (Achilles Study).
Journal of Clinical Oncology2022-06-01
Pembrolizumab Plus Platinum Chemotherapy and Radiotherapy for Unresectable, Locally Advanced, Stage 3 NSCLC: KEYNOTE-799.
2021-11-01
Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: confirmatory results from the PROCLAIM phase III clinical trial.
2021-10-016 citations
KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.
Journal of Clinical Oncology2021-05-2016 citations
Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
Journal of Clinical Oncology2020-05-2016 citations
Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer
Current Medical Research and Opinion2019-05-241 citations
Phase 2 trial of first-line pembrolizumab with platinum doublet chemotherapy and radiotherapy in patients (pts) with unresectable, locally advanced stage III non–small-cell lung cancer (NSCLC): KEYNOTE-799.
Journal of Clinical Oncology2019-05-201 citations
Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC).
Journal of Clinical Oncology2016-05-20
Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).
Journal of Clinical Oncology2015-05-2016 citations
A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC).
Journal of Clinical Oncology2015-05-201 citations
Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIMHD IL-2 National Registry.
Journal of Clinical Oncology2015-05-20
Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry.
Journal of Clinical Oncology2015-05-20